Biogen’s BIIB080 Imaging Study Completes, Marking Quiet but Key Step in Alzheimer’s Pipeline

Biogen Inc. (BIIB) announced an update on their ongoing clinical study.

Biogen Inc. (BIIB) has completed a Phase 1 study titled “A Phase 1, Open-Label Study to Determine the Biodistribution, Safety, and Tolerability of a Microdose of Radiolabeled BIIB080 Co-administered With BIIB080 in Healthy Adults.” The goal is to see how the Alzheimer’s drug candidate BIIB080 spreads in the brain and spine, and to confirm that this process is safe in healthy volunteers.

The study tests BIIB080 and a tagged version of the same drug, called radiolabeled BIIB080. Both are injected into the spinal fluid and tracked with imaging to see where the drug goes. The aim is to support the wider Alzheimer’s program by showing that BIIB080 can reach key areas tied to memory and thinking.

This is an interventional Phase 1 trial with a single treatment group and no randomization. All participants receive the same combination of BIIB080 and the radiolabeled form, and the study is open-label, so both doctors and volunteers know what is given, with the main focus on safety and drug distribution rather than direct patient benefit.

The study was first submitted in June 2024, giving investors a sense of when planning and setup began. The latest update on March 17, 2026, confirms the trial is now listed as completed, signaling that dosing and follow-up are done and Biogen can move toward analyzing data and linking it to later-stage Alzheimer’s trials.

For investors, completion of this early study helps de-risk BIIB080’s development path and supports Biogen’s broader neuroscience pipeline at a time when Alzheimer’s remains a major focus for large-cap pharma. Positive biodistribution and safety data could improve sentiment around BIIB, especially as it competes with Eli Lilly, Eisai, and others in disease-modifying Alzheimer’s treatments.

While this is a small, early study in healthy adults, it adds an important piece of evidence that may underpin future efficacy work in patients and potential partnering or licensing talks. The trial is now listed as completed and recently updated, with further details available on the ClinicalTrials portal.

To learn more about BIIB’s potential, visit the Biogen Inc. drug pipeline page.